Baker Bros. Advisors’s Arcus Biosciences RCUS Stock Holding History

Baker Bros. Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.98M	Buy	415,621 +145,621	+54%	+$3.14M	0.05%	69
2025 Q4	$6.43M	Buy	+270,000	New	+$5.51M	0.04%	69
2021 Q1	–	Sell	-72,709	Closed	-$1.89M	–	132
2020 Q4	$1.89M	Sell	72,709 -42,716	-37%	-$1.03M	0.01%	111
2020 Q3	$1.98M	Sell	115,425 -6,109	-5%	-$136K	0.01%	102
2020 Q2	$3.01M	Hold	121,534	–	–	0.01%	90
2020 Q1	$1.69M	Hold	121,534	–	–	0.01%	93
2019 Q4	$1.23M	Hold	121,534	–	–	0.01%	90
2019 Q3	$1.11M	Hold	121,534	–	–	0.01%	97
2019 Q2	$966K	Hold	121,534	–	–	0.01%	96
2019 Q1	$1.52M	Hold	121,534	–	–	0.01%	85
2018 Q4	$1.31M	Hold	121,534	–	–	0.01%	82
2018 Q3	$1.69M	Hold	121,534	–	–	0.01%	87
2018 Q2	$1.49M	Buy	+121,534	New	+$1.91M	0.01%	98

Other funds holding RCUS

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Baker Bros. Advisors's RCUS Position: Q1 2026 in Review

Baker Bros. Advisors increased its Arcus Biosciences (RCUS) stake by 54% in Q1 2026, buying an estimated $3.14M and bringing the position to 415,621 shares worth $8.98M. The position accounts for 0.05% of the portfolio, ranked #69.

Baker Bros. Advisors first reported a position in RCUS in Q2 2018 and has held it in 13 quarters since. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

Baker Bros. Advisors held 415,621 shares of Arcus Biosciences worth $8.98M as of Q1 2026.
Baker Bros. Advisors bought 145,621 Arcus Biosciences shares in Q1 2026, an estimated $3.14M.
Arcus Biosciences made up 0.05% of Baker Bros. Advisors's portfolio in Q1 2026, its #69 holding.
Baker Bros. Advisors first reported a position in Arcus Biosciences in Q2 2018 and has held it in 13 quarters since.
210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.